By Patrick Costello 

Roche Holding AG (RO.EB) said Wednesday that it has extended the offer period for its planned acquisition of the Philadelphia-based biotechnology company Spark Therapeutics Inc. (ONCE) to Sept. 3.

The Swiss pharmaceuticals company said the offer has been extended to provide additional time for the U.S. Federal Trade Commission and the U.K. Competition and Markets Authority to complete their review of Roche's pending acquisition of the company.

Roche said both parties remain committed to the deal and are working cooperatively with the FTC and CMA.

Roche's offer of $114.50 a share for all shares of Spark has been extended multiple times since it was announced in February and was set to expire Wednesday, July 31.

As of July 30, shareholders representing roughly 25.2% of Spark's outstanding shares had accepted Roche's offer, it added.


Write to Patrick Costello at


(END) Dow Jones Newswires

July 31, 2019 01:33 ET (05:33 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Roche (QX) Charts.
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Roche (QX) Charts.